Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
Friday, BridgeBio Pharma Inc. (NASDAQ:BBIO) presented additional data from an analysis of its Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM at the European Society of Cardiology (ESC) 2024.
週五，阿里拉姆製藥公司（納斯達克: BBIO）在歐洲心臟學會（ESC）2024年的阿特里布特-Cm的第三期ATTRibute-Cm和開放標籤擴展研究中公佈了額外的數據分析結果。
The data included change from baseline in serum TTR levels in participants receiving acoramidis versus those receiving tafamidis in the placebo group in ATTRibute-CM at Month 30, as well as serum TTR levels in patients who transitioned from placebo and tafamidis to acoramidis.
該數據包括在參與者接受acoramidis與在ATTRibute-Cm中接受tafamidis的安慰劑組之間的血清TTR水平變化（基線）在30個月時期的數據，以及從安慰劑和tafamidis轉換到acoramidis的患者的血清TTR水平。
Also Read: Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles.
此外阿里拉姆製藥股票在詳細介紹一個伴有心臟肌肉僵硬的病症的Vutrisiran數據後出現了下跌。
Transthyretin amyloidosis (ATTR-CM) occurs when the liver produces faulty transthyretin (TTR) proteins. Clumps of these abnormal proteins (called fibrils) build up in the heart's main pumping chamber.
當肝臟產生有缺陷的甲狀腺轉運蛋白（TTR）蛋白質時，澱粉樣蛋白性甲狀腺轉運蛋白（ATTR-CM）即出現。這些異常蛋白（稱爲纖維）的團塊在心臟的主要泵室中堆積。
In participants who switched from Pfizer Inc's (NYSE:PFE) Vyndaqel (tafamidis) and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum TTR at Month 1 of the OLE (n=21, p=0.01) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18, p=0.01).
在從輝瑞（紐交所:PFE）的Vyndaqel（tafamidis）和安慰劑轉換到阿特里布特-Cm研究的acoramidis開放標籤擴展（OLE）中的參與者中，OLE的第1個月血清TTR平均增加了3.0mg/dL（n = 21，p = 0.01），OLE的第6個月血清TTR平均增加了3.4mg/dL（n = 18，p = 0.01）。
BridgeBio submitted a marketing application to the FDA, which has been accepted with a PDUFA action date of November 29, and a marketing application to the European Medicines Agency, with a decision expected in 2025.
BridgeBio已向美國食品藥品監督管理局（FDA）提交了一份營銷申請，並在2024年11月29日獲得了審評報告，還向歐洲藥品管理局提交了一份營銷申請，預計在2025年做出決定。
BridgeBio has granted Bayer AG (OTC:BAYRY) exclusive rights to commercialize acoramidis for ATTR-CM in Europe.
BridgeBio已授予拜耳（adr）在歐洲商業化acoramidis用於ATTR-Cm的獨家權利。
Price Action: BBIO stock is up 12.50% at $27.69 at the last check on Friday.
市場表現:BBIO股票在週五最後一次檢查時上漲12.50%，報27.69美元。
- Lockheed Martin Resumes Delivery Of F-35 Jets, But US Government To Withhold Some Payment Putting Profit Margins Under Pressure.
- 洛克希德馬丁恢復交付F-35戰機，但美國政府將暫停部分支付，使得利潤率面臨壓力。